Drugs and Pharmaceuticals News - Page 3

Page 3 of Drugs and Pharmaceuticals News issued by the Send2Press® Newswire service.



Eularis Updates Reports That Help Pharmaceutical Companies Do More for Real Growth Than Simply Downsizing

LONDON, U.K. (SEND2PRESS NEWSWIRE) — The pharmaceutical industry is facing unprecedented challenges on many fronts – a slew of patient expiries, a lack of blockbusters in the pipeline to replace the patent expiries, decreasing growth in many major markets, generic competition, constantly changing regulatory and competitive environment rendering old tools for analysis obsolete, increased pressure on CEOs to deliver shareholder growth resulting in budget cuts, downsizing, and less than optimal results.

Pharmaceutical eMarketing using Social Media: How to Use It Effectively, Meet the Challenges (Regulatory and Others) and Measure Results in Dollar Terms

NEW YORK, N.Y. and LONDON, U.K. (SEND2PRESS NEWSWIRE) — Eularis is announcing the release of its report ‘How To Harness The Power Of Social Media In Pharmaceutical eMarketing.’ This report puts to rest the issues around ‘can’t,’ and shows Pharmaceutical marketers how they can utilize social media networks effectively to meet their marketing objectives.

Eularis to Address Marketing Return at Japanese Pharmaceutical Marketing Excellence Conference

TOKYO and LONDON, U.K., May 12 (SEND2PRESS NEWSWIRE) — Dr. Andree Bates, president of the New York and London-based pharmaceutical analytics company Eularis, will be delivering a presentation on how to tell if you are making the wrong marketing decision. The Pharmaceutical Marketing Excellence conference takes place in Tokyo, Japan.

New Report Examines Pharmaceutical Sales Force Effectiveness

LONDON, U.K. and NEW YORK, N.Y. – Nov. 20 (SEND2PRESS NEWSWIRE) — With the ever-increasing pressure to ensure maximum return on investment, sales force effectiveness is becoming a high priority in the global pharmaceutical industry. Reports have shown that while sales forces represent the largest spend in pharma sales and marketing, return on this investment has declined sharply in recent years.